Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Silvia Carrara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4206-9463; OpenAlex author ID A5071261627, A5152476782. Sources: ClinicalTrials.gov.

Their work

Papers
30 (first author 1, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
91
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 trial · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 5 papers · 2022: 2 papers · 2023: 8 papers · 2024: 4 papers · 2025: 2 papers · 2026: 5 papers

Papers 30

  1. Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2026.35610↗
  2. Liquid biopsy in pancreatic cancer: current advances, limitations, and future perspectives. Co-author DOI 10.1016/j.dld.2026.03.002↗
  3. Hereditary pancreatic cancer: A proposal for surveillance from the Italian Association for the Study of the Pancreas (AISP). Co-author DOI 10.1016/j.dld.2026.04.007↗
  4. Current practices, barriers and facilitators toward simultaneous care management in patients affected by pancreatic adenocarcinoma: An Italian cross-sectional … Last author DOI 10.1016/j.dld.2026.05.011↗
  5. AISP position statement: Standardising biological sample collection and handling for advanced diagnostics and multi-omic analyses in pancreatic cancer. Last author DOI 10.1016/j.dld.2026.08.021↗
  6. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  7. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  8. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  9. The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance… Co-author DOI 10.1007/s10689-024-00366-3↗
  10. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  11. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  12. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  13. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  14. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  15. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  16. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  17. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  18. Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients with Pancreatic Cancer or Suspected Related Hereditary Syndromes: Historical Prospe… Co-author DOI 10.3390/cancers15061852↗
  19. Can STEreotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer? Long-Term Clinical Outcomes, Toxicity … Co-author DOI 10.3390/curroncol30070513↗
  20. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival. Co-author DOI 10.1016/j.dld.2021.06.006↗
  21. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2022.05.006↗
  22. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  23. Side-by-side comparison of next-generation sequencing, cytology, and histology in diagnosing locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.gie.2020.06.069↗
  24. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  25. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  26. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  27. Italian registry of families at risk of pancreatic cancer: AISP Familial Pancreatic Cancer Study Group. Co-author DOI 10.1016/j.dld.2020.07.027↗
  28. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Regis… Co-author DOI 10.1038/s41395-018-0414-z↗
  29. Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. First author DOI 10.1016/j.gie.2012.08.006↗
  30. Celiac plexus block for pancreatic cancer pain in adults. Co-author DOI 10.1002/14651858.cd007519.pub2↗

Trials 1

  1. Next Generation Sequencing of Tumor Cells in Locally Advanced Pancreatic Adenocarcinoma Principal investigator NCT03578939↗

Closest collaborators

The 25 strongest of 91 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Salvatore Paiella · 7 shared papers, 2019–2026 · strength 1.40
  2. Erica Secchettin · 5 shared papers, 2020–2026 · strength 1.02
  3. Lívia Archibugi · 5 shared papers, 2023–2026 · strength 1.01
  4. Gabriele Capurso · 6 shared papers, 2019–2026 · strength 0.85
  5. Manuel Gentiluomo · 3 shared papers, 2023–2026 · strength 0.77
  6. Alessandro Zerbi · 6 shared papers, 2019–2024 · strength 0.76
  7. Massimo Falconi · 5 shared papers, 2019–2026 · strength 0.74
  8. Claudio Luchini · 2 shared papers, 2026 · strength 0.66
  9. Claudio Ricci · 3 shared papers, 2024–2026 · strength 0.59
  10. Raffaele De Luca · 2 shared papers, 2026 · strength 0.54
  11. Giovanni Butturini · 4 shared papers, 2019–2026 · strength 0.50
  12. Luigi Laghi · 4 shared papers, 2019–2024 · strength 0.49
  13. Giulia Martina Cavestro · 4 shared papers, 2019–2026 · strength 0.49
  14. Arianna Dal Buono · 3 shared papers, 2023–2026 · strength 0.48
  15. Silvia Bozzarelli · 3 shared papers, 2022–2023 · strength 0.44
  16. Marta Puzzono · 3 shared papers, 2023–2026 · strength 0.42
  17. Isabella M. Frigerio · 3 shared papers, 2019–2026 · strength 0.38
  18. Roberto Salvia · 3 shared papers, 2019–2026 · strength 0.38
  19. Fabio Casciani · 2 shared papers, 2024 · strength 0.37
  20. Paolo Giorgio Arcidiacono · 4 shared papers, 2011–2026 · strength 0.37
  21. Donatella Delle Cave · 1 shared paper, 2026 · strength 0.36
  22. Iréne Esposito · 1 shared paper, 2026 · strength 0.36
  23. Raffaele Pezzilli · 3 shared papers, 2019–2024 · strength 0.31
  24. Valentina Arcangeli · 2 shared papers, 2024–2026 · strength 0.31
  25. Giuliana Sereni · 2 shared papers, 2024–2026 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.